1-844-989-PATH (7284)
Back
Pfizer RxPathways Updates
.page-node-type-resource-type .node__content .layout:nth-of-type(2) {
background: #fff;
}
.page-node-type-resource-type .node__content .layout:nth-of-type(2):before, .page-node-type-resource-type .node__content .layout:nth-of-type(2):after {
background: #fff;
}
.page-node-type-resource-type .… Read More
Are patients who have commercial insurance eligible for the Pfizer Patient Assistance Program (PAP)?
No. Commercially insured patients (e.g., patients who get their insurance through their job or through a Federal Employer Plan) are not eligible for the PAP.
What products will remain within Pfizer PAP as of January 1, 2025?
TypePrimary CareSpecialty CareOncologyMedicinesCelontinDepo-EstradiolDuaveeEstringNorpace CRNurtecPremarinPremphasePremproSynarelTikosynTrecatorZarontinZavzpretBeneFIXCibinqoElelysoEucrisaLitfuloSomavertVelsipityVyndaqel /… Read More
Why is Pfizer adding this new requirement for patients enrolled in a Medicare Part D/Medicare Advantage Plan in 2025?
The 2025 benefit changes outlined in the Inflation Reduction Act will help many Medicare Part D/Medicare Advantage patients, including (1) the reduction of out-of-pocket prescription costs for covered medicines to $2,000 annually and (2) a voluntary option for enrollment in the Medicare… Read More
NEW & EFFECTIVE IMMEDIATELY: When is the new Certification and demonstration of MPPP enrollment and/or ICPAP denial required for Medicare Part D/Medicare Advantage patients?
All Medicare Part D/Medicare Advantage enrollees seeking access to the Pfizer Patient Assistance Program for the 2025 enrollment year, must attest to and provide evidence of their enrollment in the Medicare Prescription Payment Plan. In addition, patients must apply to all applicable ICPAPs and… Read More
NEW: Why is Pfizer requesting proof of MPPP enrollment and/or proof of denial from all applicable ICPAPs?
Pfizer’s PAP is a last resort, safety net program, for patients with the most financial need. As such, we encourage patients to explore all of their options, and if the patient’s prescription costs remain unaffordable after this, only then should patients consider applying for the PAP.